Navigation Links
New In Vitro Study Data Show That Wound Dressing With Silver Kills Multidrug-Resistant Organisms
Date:8/13/2012

SKILLMAN, N.J., Aug. 13, 2012 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of multidrug-resistant organisms (MDROs), commonly referred to as 'superbugs.' The study results were published in the August issue of the International Wound Journal.

In the in vitro study, four models designed to simulate stringent clinical conditions were used to investigate the antimicrobial efficacy of AQUACEL™ Ag dressing. The simulated wound fluid (SWF) model was used to measure sustained antimicrobial activity over time. The simulated colonized shallow wound (SCSW) model was designed to investigate the effect of dressing conformability on activity of AQUACEL™ Ag dressing. The simulated colonized wound surface (SCWS) model was used to investigate the antimicrobial activity of the AQUACEL™ Ag dressing against a variety of MDROs seeded into agar directly beneath the dressing.  The biofilm model (poloxamer) was used to assess the antimicrobial activity of the AQUACEL™ Ag dressing when each of the MDROs was expressing a biofilm phenotype. Non-silver AQUACEL™ dressing was used as a control where appropriate.(1)

Multidrug-resistant organisms tested included Acinetobacter baumannii, community-associated methicillin-resistant Staphylococcus aureus, and extended-spectrum beta-lactamase-producing bacteria. Clostridium difficile was also included because it demonstrates many of the characteristics seen in MDROs and has evidence of emerging resistance.(1)

Throughout all test methods, AQUACEL™ Ag dressing was shown to have consistent antimicrobial activity against a variety of MDROs. The authors concluded that in vitro antimicrobial efficacy of AQUACEL™ Ag dressing against a variety of MDROs could indicate a potential clinical benefit to preventing or controlling endogenous wound infections where antibiotic options are limited and tolerated by biofilm phenotypes. They further concluded that it may also act as an antimicrobial barrier to prevent the spread of such pathogens into the wider community.(1)

About AQUACEL™ and AQUACEL™ Ag Dressings
AQUACEL™ and AQUACEL™ Ag Dressings are soft, absorbent non-woven wound dressings based on Hydrofiber™ Technology. Used for a wide range of moderate to highly exuding chronic and acute wounds, including surgical, trauma and burn wounds, AQUACEL™ and AQUACEL™ Ag dressings are available in a variety of shapes, sizes and formats, including foam, pad or ribbon dressings. AQUACEL™ Ag is indicated for the management of infected wounds and wounds at risk of infection.

About ConvaTec
ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. For more information, please visit www.convatec.com.

Hydrofiber and AQUACEL are registered trademarks of ConvaTec Inc. in the U.S.
© 2012 ConvaTec Inc.

(1) Bowler P, Welsby S, Towers V, et al. Multidrug-resistant organisms, wounds and topical antimicrobial protection. Intern Wound Jour. 2012; 9(4):387-396.

 


'/>"/>
SOURCE ConvaTec
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
2. In Vitro Diagnostics: World Market Outlook 2012-2022
3. Unprecedented Study shows Berlin Heart device provides life-saving "bridge" for young children and babies
4. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
5. German-based Contract Research Organization Verum.de Opens US Office to Expand Clinical Study Services in Central and Eastern Europe for American Pharma and Biotech
6. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
7. Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
8. Asthmapolis Expands Dignity Health Study to Include Mercy Medical Group Patients
9. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
10. PCMA: New Study Finds Generic Medications Saved $1 Trillion Over the Last Decade
11. Mylan Applauds Study Highlighting $1 Trillion in Savings for U.S. Health Care System Due to Generic Drugs Over Past Decade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 ... ... the Workers Compensation Research Institute (WCRI) officially opened registration today for its ... Place Hotel in Boston, MA . , The theme of the conference is ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):